Search Results

Assembly Biosciences, Inc. today announced that it has closed the issuance of shares of its common stock and warrants to Armistice Capital LLC (“Armistice Capital”), a healthcare-focused institutional investor, and Gilead Sciences, Inc. (“Gilead”), in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, before deducting expenses.

Assembly Biosciences, Inc. announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator candidate in development for the treatment of chronic hepatitis B virus infection.

Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, reported financial results and recent highlights for the first quarter ended March 31, 2024.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will present data from its herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline programs at upcoming medical congresses.

Assembly Biosciences, Inc. today announced new data for ABI-6250, the company’s orally bioavailable, small molecule hepatitis D virus (HDV) entry inhibitor candidate, featured in a poster presentation.

Assembly Biosciences, Inc. today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.